What data from a failed IVF cycle should the clinician be reviewing with me?
A post-IVF-cycle appointment that covers only whether the transfer resulted in pregnancy is incomplete. The cycle generates a cascade of data points that, taken together, describe the specific part of the reproductive process where the limiting factor is most likely located. Each data point opens a specific clinical question.
Number of eggs retrieved relative to antral follicle count and AMH. If significantly fewer eggs were retrieved than expected from baseline reserve, the stimulation protocol may need adjustment. The question: “Were the number of eggs retrieved consistent with what you expected based on my reserve? If not, what might explain the difference?”
Fertilization rate. Normal fertilization rate with conventional IVF is 60 to 80% of mature eggs. A significantly lower rate may indicate sperm function issues and may warrant ICSI if not already used, or more detailed sperm analysis. The question: “What was our fertilization rate and how does that compare to expected?”
Embryo development to day 3 and day 5. The progression from two-pronuclear stage to blastocyst is where embryo quality most visibly expresses itself. A high attrition rate between day 3 and day 5 (blastocyst conversion below 40 to 50%) suggests embryonic genome activation failure, which is primarily an egg quality issue. The question: “What was our blastocyst conversion rate and what does that tell you about egg quality in this cycle?”
Embryo quality grades and chromosomal results. If PGT-A was performed, the proportion of euploid embryos provides the clearest picture of egg quality. In women over 38, euploid rates below 30 to 40% are common and reflect age-related chromosomal error rates. The question: “What do the PGT results tell us about the quality of the eggs from this cycle?”
Progesterone level on transfer day. Progesterone below 10 ng/mL on the day of transfer in a medicated cycle is associated with significantly lower implantation rates. Many clinics do not routinely check this value or share it proactively. The question: “What was my progesterone level on the day of transfer?”
What questions open a useful conversation about protocol changes?
Protocol change conversations require questions that are specific, forward-looking, and framed around the clinical data rather than the patient’s emotional response to the outcome. The questions below are structured to produce specific protocol discussion rather than general reassurance.
On stimulation protocol: “Based on the response to this stimulation protocol, what would you change for the next cycle? Is there a protocol that tends to produce better results for patients with my response profile?” This question invites the clinician to think forward rather than defend the past protocol.
On egg quality: “Given the blastocyst conversion rate and embryo quality from this cycle, is there anything in the preparation phase that you think we should address differently before the next retrieval? I am willing to take a preparation window before the next cycle if you think it would help.” Explicitly offering the preparation window removes the implicit assumption that the patient wants to proceed immediately and may open discussion of egg quality interventions.
On implantation environment: “We have transferred [number] good-quality embryos without success. At what point do you recommend investigating the implantation environment specifically? What would that investigation include?” This question frames implantation investigation as a forward step rather than an accusation that the clinic missed something.
On protocol timing: “Is there a reason to proceed with the next cycle immediately, or would a rest cycle with preparation work potentially produce better results? What does the data suggest?” This question gives the clinician permission to recommend the rest cycle that the patient may need, without forcing the patient to demand it against the clinic’s default momentum toward the next cycle.
What investigations are worth raising after recurrent implantation failure?
Recurrent implantation failure (RIF), commonly defined as two or more failed transfers of good-quality embryos, is the clinical presentation most likely to benefit from targeted investigation beyond standard protocol. The following investigations have the strongest evidence base for RIF specifically.
ERA (Endometrial Receptivity Analysis): A genomic test of endometrial gene expression that identifies whether the endometrium is receptive at the standard transfer timing. Approximately 25 to 30% of RIF patients are found to have a displaced implantation window requiring transfer timing adjustment. The clinical question: “We have had [number] failed transfers. Would you recommend ERA to evaluate whether my implantation window is displaced?”
Chronic endometritis testing: Chronic endometritis, an inflammation of the endometrial lining caused by bacterial infection, is present in approximately 15 to 30% of women with RIF and is undetectable by standard ultrasound. Testing requires either endometrial biopsy with CD138 staining (the gold standard) or a uterine microbiome panel. Treatment with targeted antibiotics resolves the condition in most cases. The clinical question: “Has chronic endometritis been ruled out? Would an endometrial biopsy with CD138 staining be appropriate?”
Progesterone monitoring on transfer day: Multiple studies have found that serum progesterone below 10 to 12 ng/mL on the day of embryo transfer in medicated cycles is associated with significantly lower live birth rates. The clinical question: “Would you be willing to check my progesterone on transfer day in the next cycle and adjust the support protocol if it is below the optimal range?”
Immune evaluation: Antiphospholipid antibody (APA) panel, natural killer cell activity, and thyroid antibody status have evidence for specific subpopulations with RIF. The clinical question: “Given our history of implantation failure, would you recommend an immune evaluation to rule out antibody or NK cell issues?”
How do I handle the conversation if the clinician is not engaging with the data?
Some post-cycle appointments default to reassurance and momentum toward the next cycle regardless of what questions are asked. When this pattern occurs, several specific strategies can shift the dynamic.
Ask for the specific numbers. Rather than asking interpretive questions, ask for the raw data: “What was our fertilization rate? What was our blastocyst conversion rate? What was my progesterone on transfer day?” A clinician who has not reviewed these numbers before the appointment will need to look them up, which slows the conversation and creates a natural opportunity for clinical discussion of what the numbers show.
Write down the answer and name the follow-up question it creates. When the clinician provides a number, write it down visibly and ask: “And what does that tell us?” The act of writing signals that you are treating the appointment as a clinical information-gathering session, not a routine check-in. Most clinicians respond to this signal by providing more specific information.
Ask for the appointment notes or clinical summary. Requesting that the discussion be documented in the clinical record, or asking for a patient portal summary of the post-cycle review, signals that you regard the conversation as clinically significant and will be reviewing it later. This changes the informational density of the conversation.
Request a dedicated consultation rather than a routine post-cycle visit. If the appointment is time-limited and the questions are substantive, request a longer consultation specifically for protocol review. Most clinics accommodate this request. A dedicated protocol review consultation is a different appointment than a routine post-cycle check-in, and the clinical engagement is typically deeper.
What should I do if the conversation leads to “let’s try the same protocol again”?
A recommendation to repeat the same protocol after a failed cycle is not always wrong. For some presentations, the first cycle is diagnostically informative (it establishes the response profile) and the same protocol adjusted for what was learned is the appropriate next step. The question is whether the recommendation comes with a clinical rationale or is the default in the absence of engaged review.
The distinguishing question: “What specifically about this cycle’s data supports repeating the same protocol rather than modifying it?” A clinician who can answer this with specific reference to the cycle data is providing a reasoned recommendation. A clinician who cannot answer it specifically may be defaulting to protocol momentum rather than individualized clinical decision-making.
If the recommendation to repeat the same protocol comes without a satisfactory clinical rationale after two or more failed cycles, three options are worth considering:
- A second opinion from a reproductive endocrinologist at a different clinic. A fresh clinical review from a clinician without investment in the previous protocol often surfaces protocol modifications or investigative steps that the current clinic has not prioritized.
- A consultation with a reproductive immunologist. If implantation failure has occurred with good-quality embryos, a reproductive immunologist specializes in the immunological dimensions of implantation that are outside standard RE training and often outside standard RE protocols.
- A preparation window before the next cycle. If the clinical rationale for repeating immediately is not clear, requesting a deliberate preparation window (two to three months of targeted egg quality work and regulation practice) before the next cycle is a reasonable patient-initiated proposal that most clinicians will engage with constructively.
The The Fertility Intelligence Hub Perspective
After my third failed transfer, I sat in the post-cycle appointment and asked the question I had been asking after every failed cycle: “Why didn’t it work?” And I received the answer I had received after every failed cycle: “We just do not always know. Let’s look at the next steps.”
What changed everything was when I finally stopped asking why and started asking what. Not “why didn’t this work” but “what does the data from this cycle tell us, what would need to be different next time, and what would you want to rule out before we proceed.” Those three questions produced more clinical information in one appointment than years of “why” had.
I also learned to ask about things I had never been told to ask about. What was my progesterone on transfer day? Nobody had volunteered that number in four transfer cycles. When I finally asked and found out it had been 8 ng/mL on two of those transfers, below the threshold associated with adequate luteal support, that single data point changed the entire conversation about what had been happening.
Inside The Egg Awakening, I work with women to prepare for these appointments specifically. Not to challenge their clinician, but to show up as a clinical partner who knows what data matters, what questions open the conversation, and what they are entitled to ask. The information is in the chart. The question is whether you know how to ask for it.
